 |
|
Wet AMD
Wet AMD is the leading cause of blindness in patients 60 and older due to abnormal blood vessel growth under the retina. The goal of new therapies is to preserve and improve vision and to extend treatment intervals. We place high priority on a patient's quality of life and ability to function in daily activities.
To demonstrate how drastically medical advances impact our specialty field, consider this: Less than 10 years ago, we were only able to help a small percentage of patients treated for Wet AMD. Today, thanks to advances in treatment, we see a (significant) improvement or stabilization in 95 percent of patients we treat for this condition.
Current clinical trials for Wet AMD:
Regeneron View 1
Double masked study of efficacy and safety of intravitreal VEGF Trap-Eye in subjects with wet AMD. Patients who complete Regeneron View 1 then become candidates for a subsequent study, Regeneron Clearit.
Regeneron Clearit
Investigation of efficacy and safety of intravitreal VEGF Trap-Eye in wet AMD.
VEGF Trap is a fusion protein designed to bind proteins involved in abnormal blood vessel growth in wet AMD. These studies compare treatment with VEGF Trap-Eye and Lucentis, an anti-angiogenic agent approved for use in wet AMD. The studies compare treatment with VegF Trap-EYE and Lucentis versus Lucentis alone. Lucentis is currently the only FDA-approved treatment for Wet AMD.
Genentech HARBOR
An active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0mg Ranibizumab in patients with wet AMD. This study compares the currently approved dose of Lucentis with one that is four times the concentration.
To explore this section, please choose from the menu on the left.
